Pure unadulterated BS. Cut and paste from the last filings and change a few words! I almost thought there was something possible!
The Company’s business operations consist of doing business in the cell repair and cell replacement for Equine stock only at present, but we are pursuing FDA approval for existing and modified products to be used for the repair of the Human Body. It is estimated that this process will take up to six months assuming a problem-free time-line and funds available to complete. Its products have been successfully utilised for the repair of horses tendons and have the added bonus of being patented worldwide, with an exclusive licence in the name of the Company for equine and human applications. In October 2013 we had to cease trialing the process due to lack of available and sustainable funds. The new initiative to generate investment into the company will allow us to recommence these trials and move towards selling the equine product on the open market. As a result, the Company is still in development and approval stage. Whilst we have raised the previosly estimated $2million required to obtain US Food and Drug Administration approval of the patented process for humans and to make the product available to our targeted markets our due diligence has been successfully completed and contracts now signed subject only to the remittance and clearance of funds. The new loan investment in the Company will allow trials to recommence. The delay in receiving the new funding, due to circumstances beyond our control or influence, has prevented us from pursuing the FDA approval, appointing our preferred investor relations and public relations consultants and commissioning the new website.
The Company’s business operations consist of doing business in the cell repair and cell replacement for Equine stock only at present, but we are pursuing FDA approval for existing and modified products to be used for the repair of the Human Body. It is estimated that this process will take up to six months assuming a problem-free time-line and funds available to complete. Its products have been successfully utilised for the repair of horses tendons and have the added bonus of being patented worldwide, with an exclusive licence in the name of the Company for equine and human applications. In October 2013 we had to cease trialing the process due to lack of available and sustainable funds. The new initiative to generate investment into the company will allow us to recommence these trials and move towards selling the equine product on the open market. As a result, the Company is still in development and approval stage. Whilst we have raised the previosly estimated $2million required to obtain US Food and Drug Administration approval of the patented process for humans and to make the product available to our targeted markets our due diligence has been completed and we are close to finalising the funding. The new loan investment in the Company would allow trials to recommence. The delay in receiving the new funding has prevented us from pursuing the FDA approval, appointing our preferred investor relations and public relations consultants and commissioning the new website. We have also released into the market substantial amounts of Common stock that had previously been tied up in convertible loan notes. Further increases in the authorized Common Stocks are not deemed necessary at present.
News 
Market Data 
Discover 
AI
